Search results
Found 5 matches for
First-in-human vaccine trial for deadly Nipah virus launched
Clinical Trials General Research
12 January 2024
First clinical trial participants received doses of the ChAdOx1 NipahB vaccine over the last week at University of Oxford. UK trial is first step to developing a vaccine against Nipah virus – a devastating disease mostly found in South-East Asia – that can be fatal in up to 75% of cases. The milestone clinical trial comes as the global health community marks the 25th anniversary of the first Nipah virus outbreaks. There are still no approved vaccines or treatments for the disease.
First volunteers receive vaccine for Crimean-Congo haemorrhagic fever in Oxford clinical trial
Clinical Trials Research
13 September 2023
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time. Launched on the 4th of August 2023, the clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.
African Phase I HIV vaccine trial shows encouraging preliminary results
Clinical Trials General Research
12 July 2023
The multisite Phase I HIV-CORE 006 HIV vaccine clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully.
MORU hepatitis work focusses on preventing mother-to-child transmission, high-at-risk populations, and remote communities
Clinical Trials General Research
27 July 2022
MORU Tropical Health Network researchers in Southeast Asia study various aspects of hepatitis B and C, infections that can lead to chronic liver diseases, and complications like liver cancer or cirrhosis. Researchers at MOCRU work on treatment for hepatitis C, a frequent opportunistic infection in HIV patients. MORU’s Clinical Pharmacology conducts two trials on possible treatments of hepatitis C. Hepatitis B is frequently transmitted from mother to child at birth, and SMRU researchers study mothers’ knowledge and behaviour, as well as prevention.
First-of-its-kind study found equine antitoxin is safe and effective for the treatment of tetanus in adults
Clinical Trials General Research
24 May 2022
A first-of-its kind randomised controlled trial compared two different antitoxin treatments for tetanus. A comparison of human and equine intramuscular antitoxin in adults found that intramuscular equine antitoxin is safe and effective for treating tetanus in adults. Addition of additional intrathecal (spinal) antitoxin does not add any benefit compared to treatment with intramuscular antitoxin alone.